"We are excited to have a strong presence at the upcoming International Symposium on the Autonomic Nervous System. Our platform presentation will highlight results from the previous REDWOOD trial, ...
NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today ...
Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma or tumor of the brain. While ...
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, announced today it has received a research grant ...
How can one city’s election shake up the real estate market 1,300 miles away? According to Miami developers, it’s all because ...
Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...
Queen’s researcher Dr. Sébastien Talbot, whose recent Nature paper examines the connection between nerves and tumour response, is advancing the field of cancer neuroscience.
While hospitals nationwide want to keep patients from regressing and requiring unplanned Intensive Care Unit (ICU) transfers, researchers from Northwell Health's Feinstein Institutes for Medical ...
The challenge - MapLight Therapeutics exists to open possibilities, unlocking new treatments for patients long underserved by ...
News Medical on MSN
Groundbreaking review reveals how gut microbiota influences sleep disorders through the brain-gut axis
A comprehensive review published in Brain Medicine demonstrates that disruptions in gut microbiota composition are closely linked to sleep disturbances across multiple disorders, including insomnia, ...
Launched in the summer of 1982, Diet Coke was marketed as a healthier alternative to regular soda - without the sugar or ...
Bristol Myers Squibb (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback